Full Press Release Details
BETTERING THE LIVES OF PEOPLE IMPACTED
BY KIDNEY DISEASE John P. Butler, President and CEO (Nasdaq: AKBA) September 2021 Exhibit 99.1
FORWARD-LOOKING STATEMENTS Statements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: vadadustat as a potential first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), and vadadustat's related
potential as the new oral standard of care, for the treatment of anemia due to chronic kidney disease (CKD); Akebia's cash runway funding Akebia's current operating plan through at least the next twelve months, assuming timely
regulatory approval and receipt of associated regulatory milestones; Akebia's submission of an E.U. Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and the timing thereof and any related expansion into Europe;
establishing vadadustat as a potential oral alternative to injectable erythropoiesis-stimulating agents; the U.S. market opportunity, including first-to-market potential, for vadadustat to treat patients on dialysis, and the overall opportunity
within such market; the potential for rapid adoption of vadadustat, if approved by regulatory authorities, as the first oral HIF-PHI for U.S. dialysis patients; the potential for Akebia to receive regulatory and commercial milestone payments upon
approval of vadadustat by regulatory authorities; Akebia's ability to leverage Auryxia's commercial foundation for vadadustat in CKD patients, if approved; the level of potential for vadadustat, if approved by regulatory authorities, for
the non-dialysis indication; the potential for vadadustat to be used as a therapy to prevent and lessen the severity of acute respiratory distress syndrome and in other indications where vadadustat may have therapeutic benefits and were there is
unmet need; the expansion of Akebia's pipeline and portfolio of novel therapeutics, including by leveraging new partnership relationships and Akebia's related research and development activities and engaging in internal discovery and
development; and overall market opportunity, clinical opportunity, commercial potential, prevalence, and the growth in, and potential demand for, vadadustat. The terms "believe," "expect," "goal,"
"look forward," "future," "opportunity," "planned," "potential," "will", "estimate," derivatives of these words, and similar references are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement
as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: any delays in the U.S. Food and Drug Administration's (FDA) review of, and potential approval related to, Akebia's
New Drug Application (NDA) submission for any reason, including any delay arising from the FDA's potential inability to perform and complete inspections and audits of Akebia or the suppliers, vendors or other third parties with which
Akebia works with due to the COVID-19 pandemic; the potential therapeutic benefits, safety profile, and effectiveness of Akebia's product candidates, including vadadustat; the potential indications, demand and market opportunity,
potential and acceptance of Akebia's product and product candidates, including Akebia's estimates regarding the potential market opportunity for Akebia's product, vadadustat, if approved, or any other product candidates and the
size of eligible patient populations; enrollment in clinical and preclinical studies; the timing, likelihood and content of and advice given and decisions made by health authorities, such as the U.S. Food and Drug Administration (FDA) or the
EMA, with respect to regulatory filings and approvals, including labeling or other restrictions, the potential approval of vadadustat and Akebia's outlook related thereto, and potential indications for vadadustat; the direct or indirect impact
of the COVID-19 pandemic on regulators and Akebia's business, operations, and the markets and communities in which Akebia and its partners, collaborators, vendors and customers operate; manufacturing, supply chain and quality matters and
any recalls, write-downs, impairments or other related consequences or potential consequences; hiring, training, management and retention and key personnel changes and transitional periods; the actual funding required to continue to
commercialize Akebia's commercial product, to develop and commercialize vadadustat, and to operate Akebia; market acceptance and coverage and reimbursement of Akebia's commercial product and vadadustat, if approved;
potential generic entrants for Akebia's commercial product and vadadustat, if approved; early termination of any of Akebia's collaborations; Akebia's and its collaborators' ability to satisfy their obligations
under Akebia's collaboration agreements; the competitive landscape for Akebia's commercial product and vadadustat, if approved; the scope, timing, and outcome of any legal, regulatory and administrative proceedings;
changes in the economic and financial conditions of the businesses of Akebia and its collaborations partners and vendors; expected reliance on third parties, including with respect to the development, manufacturing, supply and commercialization
of Akebia's product and product candidates; Akebia's expectations, projections and estimates regarding its capital requirements, need for additional capital, financing Akebia's future cash needs, costs, expenses, revenues, capital
resources, cash flows, financial performance, profitability, tax obligations, liquidity, growth and contractual obligations; Akebia's internal control over financial reporting and disclosure controls and procedures, and remediation of any
material weakness or deficiencies identified in its internal controls and procedures; and Akebia's intellectual property position, including its ability to obtain, maintain and enforce patent and other intellectual property protection for
Akebia's commercial product, vadadustat and any other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Annual Report on Form 10-K for
the year ended December 31, 2020, and its most recent Quarterly Report on Form 10-Q for the period ended June 30, 2021, and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. These forward-looking
statements (except as otherwise noted) speak only as of the date of this presentation, and except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained
in this presentation. Vadadustat is an investigational drug and has not yet been approved by the FDA or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare.
driving MOMENTUM 2020 2021 Positive
Phase 3 Top-line Data Reported May 2020 October 2020 Global Phase 3 Data Presented at ASN Kidney Week Pre-NDA Meeting with FDA November 2020 Global Phase 3 Program Methods Manuscripts Published in Nephrology Dialysis Transplantation & American
Heart Journal OUR HISTORY TRACK RECORD OF EXECUTION AND INNOVATION In the U.S., vadadustat is an investigational HIF PH inhibitor that is not approved by the FDA. 2010 1st CKD patient dosed with vadadustat 2007 Formed 2018 Merger with Keryx
Biopharmaceuticals Lasker Award honors HIF researchers 2016 2019 Nobel Prize in Medicine awarded to HIF researchers 2015 Phase 3 Program initiated for vadadustat & 3 August 2020 launched in Japan September 2020 Phase 3 Top-line Data Reported
HIF-PH or HIF-PHI is hypoxia-inducible
factor prolyl hydroxylase inhibitor. NDA is New Drug Application. PDUFA is Prescription Drug User Fee Act. 1. In June 2020, Akebia announced an investigator-sponsored clinical study by UTHealth of vadadustat for ARDS. This study is being conducted
under an Investigational New Drug application (IND) with UTHealth as the study sponsor. 2. Cash, cash equivalents and available-for-sale securities as of June 30, 2021 were $247.0 million. The Company believes that its cash resources will be
sufficient to fund its current operating plan through at least the next twelve months. Additionally, the Company believes its cash runway would extend beyond the next twelve months assuming timely regulatory approval of vadadustat and the receipt of
associated regulatory milestones. UNDER FDA REVIEW VADADUSTAT FOR ANEMIA DUE TO CKD DIALYSIS NON-DIALYSIS CLINICAL PROGRAM VADADUSTAT INDICATION EXPANSION ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)1 COMMERCIAL PROGRAM AURYXIA (ferric citrate)
HYPERPHOSPHATEMIA FOR CKD IRON DEFICIENCY ANEMIA (IDA) FOR CKD FUNDING THROUGH AT LEAST THE NEXT 12 MONTHS2 NDA Filed; PDUFA Date: march 29, 2022 phase 3 results Published in New England Journal of Medicine VADADUSTAT 5 POTENTIAL FIRST-IN-CLASS ORAL
HIF-PH INHIBITOR FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD) KEY VALUE DRIVERS AKEBIA TODAY DRIVING MOMENTUM
ESKD is End Stage Kidney Disease. ESA
is erythropoiesis-stimulating agent. EPO is erythropoietin. Sources: 1 . Stauffer et al, PLOSONE, 2014. 2 2020 USRDS Annual Data Report: https://adr.usrds.org/2020/reference-tables. BURDEN OF DISEASE Quality of life: fatigue, weakness, dizziness,
shortness of breath CLINICAL IMPACT Anemia due to CKD can contribute to risk of ESKD, cardiovascular (CV) disease, stroke, cognitive impairment, CV-related complications and death CURRENT STANDARD OF CARE Consists of injectable ESAs which have been
associated with frequent hemoglobin overshoots, supra physiologic elevations of EPO, delivered through inconvenient injectable administration ANEMIA DUE TO CKD: UNMET NEEDS 5.7M PEOPLE IN THE U.S. DIAGNOSED WITH ANEMIA DUE TO CKD1 6
In the U.S., vadadustat is an
investigational HIF- PH inhibitor that is not approved by the FDA. An oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) designed to stimulate endogenous EPO production; Based on Nobel Prize winning science Positioned to be
potential oral standard of care; Potential oral alternative to injectable ESAs First HIF-PHI to have global Phase 3 results published in peer-reviewed journal (New England Journal of Medicine) Experienced nephrology focused salesforce complemented
by strong commercial partnerships with industry leaders INNOVATIVE MoA CONVENIENT ORAL DOSING ROBUST CLINICAL RESULTS COMMERCIAL BREADTH MoA is mechanism of action. EPO is erythropoietin. 7 VADADUSTAT POTENTIAL FIRST-IN-CLASS ORAL HIF-PHI
Vadadustat is not approved by the FDA.
POTENTIAL NEW ORAL STANDARD OF CARE FOR ANEMIA DUE TO CKD An oral HIF-PH inhibitor designed to stimulate endogenous EPO production CLINICAL DATA HAS SHOWN THAT VADADUSTAT: Increased hemoglobin in predictable and controlled manner Minimized
hemoglobin overshoots Maintained EPO within physiologic range Sources: Data from: Akebia's global Phase 3 program which included two separate programs, INNO2VATE and PRO2TECT. Both INNO2VATE and PRO2TECT were global, multicenter, open label
(sponsor blind), active-controlled (darbepoetin alfa - an injectable erythropoiesis stimulating agent (ESA)), non-inferiority studies, which were published in the New England Journal of Medicine in April 2021. Akebia's Phase 1 Study in Normal
Healthy Volunteers (CI-0002). Akebia's Phase 2b Study in Dialysis-Dependent CKD Patients (CI-0011). 8 VADADUSTAT ROBUST AND HIGHLY DIFFERENTIATING CLINICAL DATA
Positive global Phase 3 data
demonstrated the efficacy and cardiovascular safety of vadadustat compared to darbepoetin alfa in adult patients with anemia due to CKD on dialysis, including prevalent and incident patients. Met Primary Efficacy Endpoint: Mean Change from Baseline
in HGB Levels: Dialysis Dependent CKD Patients INNO2VATE Phase 3 Correction/Conversion (369 Incident DD-CKD Patients)1,2 Met Primary Efficacy Endpoint: Mean Change from Baseline in HGB Levels: Dialysis Dependent CKD Patients INNO2VATE Phase 3
Conversion (3,554 Prevalent DD-CKD Patients)1,2 Source: 1. K.-U. Eckardt, et al. Global Phase 3 Clinical Trials of Vadadustat for Treatment of Anemia in Patients With Dialysis-Dependent Chronic Kidney Disease (DD-CKD). Presented at: American Society
of Nephrology Kidney Week; October 22, 2020. (Akebia's Phase 3 randomized, open-label, active-controlled non-inferiority study assessed the efficacy and safety of vadadustat compared to darbepoetin alfa in 3,923 dialysis-dependent subjects
with anemia due to CKD, with a treatment duration of 52 weeks.) 2 K.-U. Eckardt, et al. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 384 1601-12. DOI: 10:1056/NEJMoa2025956 Met All Primary and Key
Secondary Safety (MACE) Endpoints: Dialysis Dependent CKD Patients INNO2VATE Phase 3 Studies (Prevalent and Incident DD-CKD Patients)1,2 Mean (SEM) change from baseline, g/dL Difference (vadadustat - darbepoetin alfa) Weeks 24-36 -0.31 (0.11) (95%
CI, -0.53 to -0.10) Weeks 40-52 -0.07 (0.13) (95% CI, -0.34 to 0.19) Mean (SEM) change from baseline, g/dL Difference (vadadustat - darbepoetin alfa) Weeks 24-36 -0.17 (0.03) (95% CI, -0.23 to -0.10) Weeks 40-52 -0.18 (0.03) (95% CI, -0.25 to -0.12)
9 VADADUSTAT GLOBAL PHASE 3 RESULTS: DIALYSIS MACE is the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke. All MACE safety endpoints were adjudicated by a committee blinded to treatment assignment.
VADADUSTAT Positive global Phase 3 data
demonstrated the efficacy of vadadustat compared to darbepoetin alfa in adult patients with anemia due to CKD not on dialysis; however, vadadustat did not meet the primary safety (MACE) endpoint of the PRO2TECT studies. (Prevalent and Incident
Populations) Source: 1. G. Chertow, et al. Global Phase 3 Clinical Trials of Vadadustat for Treatment of Anemia in Patients With Non-Dialysis-Dependent Chronic Kidney Disease. Presented at: American Society of Nephrology Kidney Week; October
22, 2020. (Akebia's Phase 3 randomized, open-label, active-controlled non-inferiority study assessed the efficacy and safety of vadadustat compared to darbepoetin alfa in 3,471 non-dialysis-dependent subjects with anemia due to CKD, with a
treatment duration of 52 weeks.) 2. G. Chertow, et al. Vadadustat in Patients with Anemia and Non-Dialysis Dependent CKD. N Engl J Med 2021; 384 1589-600. DOI: 10:1056/NEJMoa2035938 3. Akebia's ASN Investor Briefing Webcast October 23, 2020.
12 Met Primary Efficacy Endpoint: Mean Change from Baseline in HGB Levels: Non-Dialysis Dependent CKD Patients PRO2TECT Phase 3 ESA-Treated Trial (N=1725)1,2 Met Primary Efficacy Endpoint: Mean Change from Baseline in HGB Levels: Non-Dialysis
Dependent CKD Patients PRO2TECT Phase 3 ESA-Untreated Trial (N=1751)1,2 Mean change from baseline, g/dL Difference (vadadustat - darbepoetin alfa) Weeks 24-36 -0.01 (95% CI, -0.09 to 0.07) Weeks 40-52 0.00 (95% CI, -0.10 to 0.09) Mean change from
baseline, g/dL Difference (vadadustat - darbepoetin alfa) Weeks 24-36 0.05 (95% CI, -0.04 to 0.15 ) Weeks 40-52 0.04 (95% CI, -0.06 to 0.14) PURSUING A BROAD LABEL FOR PATIENTS NOT ON DIALYSIS Cardiovascular Data Analysis: PRO2TECT Studies Global,
US and Ex-US Region was a randomization stratification variable and a prespecified subgroup analysis. Age as a dichotomous variable (<65, 65) in the prespecified Cox model.3 631 MACE events yields ~80% power to show non-inferiority
assuming a true hazard ratio of 1.0. Expanded MACE is composite of MACE plus hospitalization for heart failure or thromboembolic event excluding vascular access failure. CV MACE is composite of cardiovascular mortality, nonfatal myocardial
infarction, and non-fatal stroke.
23 VADADUSTAT PEER REVIEWED
PUBLICATIONS OF GLOBAL PHASE 3 DATA AND RESULTS Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis April 2021 Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD April 2021 ASN Webcast October 23, 2020
ASN Presentation October 23, 2020 Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics May 2021 Global Phase 3 programme of vadadustat for treatment of
anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trial November 2020
$2 Billion Estimated U.S. Dialysis
Market Opportunity2 Sources: 1. 2020 USRDS Annual Data Report: https://adr.usrds.org/2020/reference-tables. 2 Based on internal estimates and industry reports estimating ESA pricing. Unique market dynamics; Dialysis center clinical protocols Approx.
556K U.S. patients on dialysis; 90% treated for anemia due to CKD1 Unmet clinical needs of CKD patients on dialysis Fast-growing home dialysis market 10 VADADUSTAT U.S. DIALYSIS MARKET
Secure U.S. approval *Pursuant to
the Vifor Amended Agreement, Akebia granted Vifor (International) Ltd. ("Vifor Pharma") an exclusive license to sell vadadustat to Fresenius Kidney Care and to certain other third party dialysis organizations in the U.S., upon approval
of vadadustat by the FDA, the earlier of reimbursement under TDAPA (defined below) or inclusion in the ESRD bundle and a milestone payment from Vifor. Source: 1 TDAPA: Transitional drug add-on payment adjustment, CMS Ruling CMS-1691-F. Medicare
Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics
and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments to Correct Existing Regulations Related to the CBP for Certain DMEPOS. NEAR TERM Secure TDAPA1 reimbursement 15 VADADUSTAT Positioned for
potential RAPID ADOPTION as first oral HIF-PHI for U.S. dialysis patients FIRST-TO-MARKET POTENTIAL POSITIONS VADADUSTAT FOR SIGNIFICANT OPPORTUNITY IN $2B U.S. DIALYSIS MARKET STRATEGIC INITIATIVES Become oral standard of care in large dialysis
operators (LDOs) and across all home dialysis programs TIW is three times weekly. Leverage exclusive U.S. distribution channel into Fresenius Kidney* Care (FKC) with
*Pursuant to the Vifor Amended
Agreement, Akebia granted Vifor (International) Ltd. ("Vifor Pharma") an exclusive license to sell vadadustat to Fresenius Kidney Care and to certain other third party dialysis organizations in the U.S., upon approval of vadadustat by
the FDA, the earlier of reimbursement under TDAPA (defined below) or inclusion in the ESRD bundle and a milestone payment from Vifor. Source: 1 TDAPA: Transitional drug add-on payment adjustment, CMS Ruling CMS-1691-F. Medicare Program; End-Stage
Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies
(DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments to Correct Existing Regulations Related to the CBP for Certain DMEPOS. NEAR TERMLONG TERM Secure TDAPA1 reimbursement 15 VADADUSTAT Leverage exclusive U.S.
distribution channel into Fresenius Kidney* Care (FKC) with Secure U.S. approval TIW is three times weekly. Become oral standard of care in large dialysis operators (LDOs) and across all home dialysis programs Submit sNDA to FDA for vadadustat for
TIW dosing regimen Expand into Europe with FIRST-TO-MARKET POTENTIAL POSITIONS VADADUSTAT FOR SIGNIFICANT OPPORTUNITY IN $2B U.S. DIALYSIS MARKET STRATEGIC INITIATIVES Become oral standard of care for in-center and home dialysis patients
*Pursuant to the Vifor Amended
Agreement, Akebia granted Vifor (International) Ltd. ("Vifor Pharma") an exclusive license to sell vadadustat to Fresenius Kidney Care and to certain other third party dialysis organizations in the U.S., upon approval of vadadustat by